Skip to main content
SpringerLink
Log in

Genomic Pathology of Lung Cancer

  • Chapter
  • First Online:
Cancer Genomics

Abstract

Genome-wide studies of lung cancer began with RNA expression microarrays, followed by DNA copy number microarrays. More recently, microRNA profiling and high-throughput sequencing studies have entered the arena. Cancer genomics is a quickly moving field. Here, we summarize the pertinent findings of lung cancer genomics studies to date, with an emphasis on diagnostic, prognostic, and predictive findings that have been validated or confirmed by multiple studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90

    Article  PubMed  Google Scholar 

  2. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442–e442

    Article  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300

    Article  PubMed  Google Scholar 

  4. Ag TI (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO Publications, Lyon

    Google Scholar 

  5. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ 321(7257):323–329

    Article  PubMed  CAS  Google Scholar 

  6. Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers–a different disease. Nat Rev Cancer 7(10):778–790

    Article  PubMed  CAS  Google Scholar 

  7. ValliÃ\( \ddot{\rm r} \)es E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P (2009) The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4(9):1049–1059

    Article  Google Scholar 

  8. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544

    Article  PubMed  Google Scholar 

  9. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2(8):706–714

    Article  PubMed  Google Scholar 

  10. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Marcus PM, Gareen IF, Gatsonis C, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409

    Article  PubMed  Google Scholar 

  11. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA (2011) Non-small-cell lung cancer. Lancet 378(9804):1727–1740

    Article  PubMed  Google Scholar 

  12. NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26(28):4617–4625

    Article  Google Scholar 

  13. Visbal AL, Leighl NB, Feld R, Shepherd FA (2005) Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest 128(4):2933–2943. doi:128/4/2933 [pii] 10.1378/chest.128.4.2933

    Article  PubMed  CAS  Google Scholar 

  14. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655. doi:97/9/643 [pii] 10.1093/jnci/dji112

    Article  PubMed  CAS  Google Scholar 

  15. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(28):6829–6837. doi:JCO.2005.01.0793[pii]10.1200/JCO.2005.01.0793

    Article  PubMed  CAS  Google Scholar 

  16. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4):752–760. doi: mdm003[pii]10.1093/annonc/mdm003

    Article  PubMed  CAS  Google Scholar 

  17. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14(13):4275–4283

    Article  PubMed  CAS  Google Scholar 

  18. Camidge DR, Kono SA, Flacco A, Tan A-C, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16(22):5581–5590

    Article  PubMed  CAS  Google Scholar 

  19. Subramanian J, Govindan R (2007) Lung cancer in never smokers: a review. J Clin Oncol 25(5):561–570

    Article  PubMed  Google Scholar 

  20. Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, Tavecchio L, Brambilla C, Field JK, Hainaut P (2012) Prognostic value of TP53, KRAS and EGFR mutations in non-small cell lung cancer: EUELC cohort. Eur Respir J 40:177–184. doi: 09031936.00097311[pii]10.1183/09031936.00097311

    Article  PubMed  CAS  Google Scholar 

  21. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18(4):1167–1176. doi: 10.1158/1078-0432.CCR-11-2109

    Article  PubMed  CAS  Google Scholar 

  22. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075

    Article  PubMed  CAS  Google Scholar 

  23. Yousem SA, Nikiforova M, Nikiforov Y (2008) The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 32(9):1317–1321

    Article  PubMed  Google Scholar 

  24. Suda K, Tomizawa K, Mitsudomi T (2010) Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29(1):49–60

    Article  PubMed  CAS  Google Scholar 

  25. Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6(2):201–205

    Article  PubMed  CAS  Google Scholar 

  26. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566. doi: nature05945[pii]10.1038/nature05945

    Article  PubMed  CAS  Google Scholar 

  27. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L, Pennypacker S, Zou Y, Sharma M, North JP, Vemula SS, Mauro TM, Neuhaus IM, Leboit PE, Hur JS, Park K, Huh N, Kwok PY, Arron ST, Massion PP, Bale AE, Haussler D, Cleaver JE, Gray JW, Spellman PT, South AP, Aster JC, Blacklow SC, Cho RJ (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 108(43):17761–17766. doi: 1114669108[pii]10.1073/pnas.1114669108

    Article  PubMed  CAS  Google Scholar 

  28. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68(17):6913–6921. doi: 10.1158/0008-5472.CAN-07-5084

    Article  PubMed  CAS  Google Scholar 

  29. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y (2006) PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54(2):209–215. doi: 10.1016/j.lungcan.2006.07.006

    Article  PubMed  Google Scholar 

  30. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554. doi: 10.1126/science.1096502

    Article  PubMed  CAS  Google Scholar 

  31. Ohgaki H, Kros JM, Okamoto Y, Gaspert A, Huang H, Kurrer MO (2004) APC mutations are infrequent but present in human lung cancer. Cancer Lett 207(2):197–203. doi: 10.1016/j.canlet.2003.10.020

    Article  PubMed  CAS  Google Scholar 

  32. Newnham GM, Conron M, McLachlan S, Dobrovic A, Do H, Li J, Opeskin K, Thompson N, Wright GM, Thomas DM (2011) Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer 11:93–93

    Article  PubMed  Google Scholar 

  33. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15(16):5216–5223. doi: 1078-0432.CCR-09-0802[pii]10.1158/1078-0432.CCR-09-0802

    Article  PubMed  CAS  Google Scholar 

  34. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115(8):1723–1733. doi: 10.1002/cncr.24181

    Article  PubMed  CAS  Google Scholar 

  35. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu X-Y, Pao W, Chen H, Ji H (2011) Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 6(11):e28204–e28204

    Article  PubMed  CAS  Google Scholar 

  36. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28(30):4616–4620

    Article  PubMed  Google Scholar 

  37. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22(4):508–515. doi: modpathol20092[pii]10.1038/modpathol.2009.2

    Article  PubMed  CAS  Google Scholar 

  38. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22(6):1103–1109. doi: 10.1200/JCO.2004.08.158

    Article  PubMed  CAS  Google Scholar 

  39. Coate LE, John T, Tsao MS, Shepherd FA (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10(10):1001–1010. doi: 10.1016/S1470-2045(09)70155-X

    Article  PubMed  CAS  Google Scholar 

  40. da Cunha Santos G, Shepherd FA, Tsao MS (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6:49–69. doi: 10.1146/annurev-pathol-011110-130206

    Article  PubMed  CAS  Google Scholar 

  41. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900–5909. doi: 10.1200/JCO.2005.02.857

    Article  PubMed  CAS  Google Scholar 

  42. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T (2009) Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4(1):22–29. doi: 10.1097/JTO.0b013e3181914111

    Article  PubMed  Google Scholar 

  43. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ, Sculier JP (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92(1):131–139. doi: 6602258[pii]10.1038/sj.bjc.6602258

    Article  PubMed  CAS  Google Scholar 

  44. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA (2007) Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25(33):5240–5247. doi: 25/33/5240[pii]10.1200/JCO.2007.12.6953

    Article  PubMed  Google Scholar 

  45. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98(12):1817–1824. doi: 10.1111/j.1349-7006.2007.00607.x

    Article  PubMed  CAS  Google Scholar 

  46. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. doi: 10.1056/NEJMoa0810699

    Article  PubMed  CAS  Google Scholar 

  47. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16(22):5489–5498. doi: 10.1158/1078-0432.CCR-10-1371

    Article  PubMed  CAS  Google Scholar 

  48. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4(120):120ra117. doi: 10.1126/scitranslmed.3003316

    Article  CAS  Google Scholar 

  49. Belani CP (2010) The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest 28(4):413–423. doi: 10.3109/07357901003631072

    PubMed  CAS  Google Scholar 

  50. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22(18):2812–2822. doi: 10.1038/sj.onc.1206388

    Article  PubMed  CAS  Google Scholar 

  51. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2(11):e313. doi: 10.1371/journal.pmed.0020313

    Article  PubMed  CAS  Google Scholar 

  52. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1):e17. doi: 10.1371/journal.pmed.0020017

    Article  PubMed  CAS  Google Scholar 

  53. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P (2008) Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 3(8):832–839. doi: 10.1097/JTO.0b013e31818071f3

    Article  PubMed  Google Scholar 

  54. Sasaki T, Rodig SJ, Chirieac LR, Janne PA (2007) The biology and treatment of EML4- ALK non-small cell lung cancer. Eur J Cancer 46(10):1773–1780. doi: S0959-8049(10)00305-9[pii]10.1016/j.ejca.2010.04.002

    Article  CAS  Google Scholar 

  55. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 108(18):7535–7540. doi: 1019559108[pii]10.1073/pnas.1019559108

    Article  PubMed  CAS  Google Scholar 

  56. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, Moran L, Mohemmad QK, Anjum R, Wang Y, Narasimhan NI, Dalgarno D, Shakespeare WC, Miret JJ, Clackson T, Rivera VM (2011) Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 78(6):999–1005. doi: 10.1111/j.1747-0285.2011.01239.x

    Article  PubMed  CAS  Google Scholar 

  57. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H, Group, A.L.K.L.C.S (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734–1739

    Article  PubMed  CAS  Google Scholar 

  58. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Janne PA (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71(18):6051–6060. doi: 10.1158/0008-5472.CAN-11-1340

    Article  PubMed  CAS  Google Scholar 

  59. Lockwood WW, Chari R, Chi B, Lam WL (2006) Recent advances in array comparative genomic hybridization technologies and their applications in human genetics. Eur J Human Genet 14(2):139–148

    Article  CAS  Google Scholar 

  60. Costa JL, Meijer G, Ylstra B, Caldas C (2008) Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. Semin Radiat Oncol 18(2):98–104

    Article  PubMed  Google Scholar 

  61. Garnis C, Campbell J, Davies JJ, Macaulay C, Lam S, Lam WL (2005) Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. Hum Mol Genet 14(4):475–482

    Article  PubMed  CAS  Google Scholar 

  62. Garnis C, Davies JJ, Buys TPH, Tsao M-S, MacAulay C, Lam S, Lam WL (2005) Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene 24(30):4806–4812

    Article  PubMed  CAS  Google Scholar 

  63. Coe BP, Henderson LJ, Garnis C, Tsao MS, Gazdar AF, Minna J, Lam S, Macaulay C, Lam WL (2005) High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. Genes Chromosomes Cancer 42(3):308–313. doi: 10.1002/gcc.20137

    Article  PubMed  CAS  Google Scholar 

  64. Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, Snijders A, Albertson DG, Pinkel D, Marra MA, Ling V, MacAulay C, Lam WL (2004) A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 36(3):299–303

    Article  PubMed  CAS  Google Scholar 

  65. Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Strumpf D, Jurisica I, Lam WL, Tsao MS (2008) Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci USA 105(29):10155–10160. doi: 0709618105[pii]10.1073/pnas.0709618105

    Article  PubMed  CAS  Google Scholar 

  66. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893–898. doi: nature06358[pii]10.1038/nature06358

    Article  PubMed  CAS  Google Scholar 

  67. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O’Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I Jr, Ribeiro U, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238–1242. doi: ng.465[pii]10.1038/ng.465

    Article  PubMed  CAS  Google Scholar 

  68. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL (2007) Resolving the resolution of array CGH. Genomics 89(5):647–653

    Article  PubMed  CAS  Google Scholar 

  69. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, Singer S, Sander C (2008) Functional copy-number alterations in cancer. PLoS One 3(9):e3179–e3179

    Article  PubMed  CAS  Google Scholar 

  70. Yim S-H, Kim T-M, Hu H-J, Kim J-H, Kim B-J, Lee J-Y, Han B-G, Shin S-H, Jung S-H, Chung Y-J (2010) Copy number variations in East-Asian population and their evolutionary and functional implications. Hum Mol Genet 19(6):1001–1008

    Article  PubMed  CAS  Google Scholar 

  71. Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U, Ralfkiaer U, Mansouri M, Buhl AM, Smedby KEM, Hjalgrim H, Syvänen A-C, Borg A, Isaksson A, Jurlander J, Juliusson G, Rosenquist R (2008) Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia–a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 47(8):697–711

    Article  PubMed  CAS  Google Scholar 

  72. Vucic EA, Thu KL, Williams AC, Lam WL, Coe BP (2010) Copy number variations in the human genome and strategies for analysis. Methods Mol Biol 628:103–117

    Article  PubMed  CAS  Google Scholar 

  73. Alkan C, Coe BP, Eichler EE (2011) Genome structural variation discovery and genotyping. Nat Rev Genet 12(5):363–376

    Article  PubMed  CAS  Google Scholar 

  74. Balsara BR, Testa JR (2002) Chromosomal imbalances in human lung cancer. Oncogene 21(45):6877–6883

    Article  PubMed  CAS  Google Scholar 

  75. Hoglund M, Gisselsson D, Hansen GB, Mitelman F (2004) Statistical dissection of cytogenetic patterns in lung cancer reveals multiple modes of karyotypic evolution independent of histological classification. Cancer Genet Cytogenet 154(2):99–109. doi: S0165-4608(04)00067-6[pii]10.1016/j.cancergencyto.2004.01.030

    Article  PubMed  CAS  Google Scholar 

  76. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL (2006) High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118(6):1556–1564. doi: 10.1002/ijc.21491

    Article  PubMed  CAS  Google Scholar 

  77. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 102(27):9625–9630. doi: 0504126102[pii]10.1073/pnas.0504126102

    Article  PubMed  CAS  Google Scholar 

  78. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schottle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansen S, Rauh D, Baessmann I, Altmuller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sanger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nurnberg P, Perner S, Thomas RK (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2(62):62ra93. doi: 2/62/62ra93[pii]10.1126/scitranslmed.3001451

    Article  PubMed  CAS  Google Scholar 

  79. Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, Smith WI Jr, Meltzer P, Giaccone G (2010) Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA 107(29):13040–13045. doi: 1008132107[pii]10.1073/pnas.1008132107

    Article  PubMed  CAS  Google Scholar 

  80. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM (2009) Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 9:237. doi: 1471-2407-9-237[pii]10.1186/1471-2407-9-237

    Article  PubMed  CAS  Google Scholar 

  81. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J, Williams AC, Hwang D, Zhu C-Q, Buys TPH, Yee J, English JC, Macaulay C, Tsao M-S, Gazdar AF, Minna JD, Lam S, Lam WL (2010) Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 7(7):e1000315–e1000315

    Article  PubMed  CAS  Google Scholar 

  82. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, Martinet N, Thibault C, Huelsken J, Brambilla E, du Manoir S (2010) SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5(1):e8960. doi: 10.1371/journal.pone.0008960

    Article  PubMed  CAS  Google Scholar 

  83. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63(21):7113–7121

    PubMed  CAS  Google Scholar 

  84. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL (2011) Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 24(10):1348–1359

    Article  PubMed  Google Scholar 

  85. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, Gray JW (2002) Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62(13):3636–3640

    PubMed  CAS  Google Scholar 

  86. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K, Lee J, Choi YL, Sato M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD, Pollack JR (2008) Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27(25):3635–3640. doi: 1211012[pii]10.1038/sj.onc.1211012

    Article  PubMed  CAS  Google Scholar 

  87. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM (2010) Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 5(4):442–447

    Article  PubMed  Google Scholar 

  88. Coe BP, Lee EH, Chi B, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL (2006) Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines. Genes Chromosomes Cancer 45(1):11–19. doi: 10.1002/gcc.20260

    Article  PubMed  CAS  Google Scholar 

  89. Olejniczak ET, Van Sant C, Anderson MG, Wang G, Tahir SK, Sauter G, Lesniewski R, Semizarov D (2007) Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res MCR 5(4):331–339

    Article  CAS  Google Scholar 

  90. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, Minna JD, Pollack JR (2006) Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25(1):130–138

    Article  PubMed  CAS  Google Scholar 

  91. Coe BP, Lockwood WW, Girard L, Chari R, Macaulay C, Lam S, Gazdar AF, Minna JD, Lam WL (2006) Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 94(12):1927–1935

    Article  PubMed  CAS  Google Scholar 

  92. Peng W-X, Shibata T, Katoh H, Kokubu A, Matsuno Y, Asamura H, Tsuchiya R, Kanai Y, Hosoda F, Sakiyama T, Ohki M, Imoto I, Inazawa J, Hirohashi S (2005) Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung. Cancer Sci 96(10):661–667

    Article  PubMed  CAS  Google Scholar 

  93. Ullmann R, Schwendel A, Klemen H, Wolf G, Petersen I, Popper HH (1998) Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization. Hum Pathol 29(10):1145–1149. doi: S0046-8177(98)90428-2[pii]

    Article  PubMed  CAS  Google Scholar 

  94. Lonergan KM, Chari R, Coe BP, Wilson IM, Tsao M-S, Ng RT, Macaulay C, Lam S, Lam WL (2010) Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE. PLoS One 5(2):e9162–e9162

    Article  PubMed  CAS  Google Scholar 

  95. Garnis C, MacAulay C, Lam S, Lam W (2004) Genetic alteration on 8q distinct from MYC in bronchial carcinoma in situ lesions. Lung Cancer 44(3):403–404

    Article  PubMed  Google Scholar 

  96. van Boerdonk RA, Sutedja TG, Snijders PJ, Reinen E, Wilting SM, van de Wiel MA, Thunnissen FE, Duin S, Kooi C, Ylstra B, Meijer CJ, Meijer GA, Grunberg K, Daniels JM, Postmus PE, Smit EF, Heideman DA (2011) DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. Am J Respir Crit Care Med 184(8):948–956. doi: 201102-0218OC[pii]10.1164/rccm.201102-0218OC

    Article  PubMed  CAS  Google Scholar 

  97. Schneider KU, Dietrich D, Fleischhacker M, Leschber G, Merk J, Schäper F, Stapert HR, Vossenaar ER, Weickmann S, Liebenberg V, Kneip C, Seegebarth A, Erdogan F, Rappold G, Schmidt B (2011) Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer 11:102–102

    Article  PubMed  CAS  Google Scholar 

  98. Kerr KM (2001) Pulmonary preinvasive neoplasia. J Clin Pathol 54(4):257–271

    Article  PubMed  CAS  Google Scholar 

  99. Lantuéjoul S, Salameire D, Salon C, Brambilla E (2009) Pulmonary preneoplasia–sequential molecular carcinogenetic events. Histopathology 54(1):43–54

    Article  Google Scholar 

  100. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JHM, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier J-P, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang P-C, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D (2011) International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285

    Article  PubMed  Google Scholar 

  101. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, Matsuno Y, Tsuchiya R, Kanai Y, Kondo T, Imoto I, Inazawa J, Hirohashi S (2005) Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 11(17):6177–6185. doi: 11/17/6177[pii]10.1158/1078-0432.CCR-05-0293

    Article  PubMed  CAS  Google Scholar 

  102. Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W, Postma DS, Groen HJ, van den Berg A (2009) Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer 66(3):372–378. doi: S0169-5002(09)00115-9[pii]10.1016/j.lungcan.2009.02.017

    Article  PubMed  Google Scholar 

  103. Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H (2009) Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 15(5):1566–1574. doi: 1078-0432.CCR-08-2188[pii]10.1158/1078-0432.CCR-08-2188

    Article  PubMed  CAS  Google Scholar 

  104. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139. doi: 10.1056/NEJMoa040938NEJMoa040938[pii]

    Article  PubMed  CAS  Google Scholar 

  105. Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25(5):587–595. doi: 25/5/587[pii]10.1200/JCO.2006.07.3585

    Article  PubMed  CAS  Google Scholar 

  106. Thomas RK, Weir B, Meyerson M (2006) Genomic approaches to lung cancer. Clin Cancer Res 12(14 Pt 2):4384s–4391s. doi: 12/14/4384s[pii]10.1158/1078-0432.CCR-06-0098

    Article  PubMed  CAS  Google Scholar 

  107. Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG (2008) Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol 3(1):84–93. doi: 10.1097/JTO.0b013e31815efe2401243894-200801000-5[pii]

    Article  PubMed  Google Scholar 

  108. Dalton WS, Friend SH (2006) Cancer biomarkers–an invitation to the table. Science 312(5777):1165–1168. doi: 312/5777/1165[pii]10.1126/science.1125948

    Article  PubMed  CAS  Google Scholar 

  109. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, Petersen I (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98(24):13784–13789. doi: 10.1073/pnas.241500798241500798[pii]

    Article  PubMed  CAS  Google Scholar 

  110. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8(8):816–824. doi: 10.1038/nm733nm733[pii]

    PubMed  CAS  Google Scholar 

  111. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98(24):13790–13795. doi: 10.1073/pnas.191502998191502998[pii]

    Article  PubMed  CAS  Google Scholar 

  112. Miura K, Bowman ED, Simon R, Peng AC, Robles AI, Jones RT, Katagiri T, He P, Mizukami H, Charboneau L, Kikuchi T, Liotta LA, Nakamura Y, Harris CC (2002) Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 62(11):3244–3250

    PubMed  CAS  Google Scholar 

  113. Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, Lu C, Woodgett J, Seiden I, Johnston M, Keshavjee S, Darling G, Winton T, Breitkreutz BJ, Jorgenson P, Tyers M, Shepherd FA, Tsao MS (2002) Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62(11):3005–3008

    PubMed  CAS  Google Scholar 

  114. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S, Richards WG, Sugarbaker DJ, Bueno R (2002) Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62(17):4963–4967

    PubMed  CAS  Google Scholar 

  115. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33(1):49–54. doi: 10.1038/ng1060ng1060[pii]

    Article  PubMed  CAS  Google Scholar 

  116. Blackhall FH, Wigle DA, Jurisica I, Pintilie M, Liu N, Darling G, Johnston MR, Keshavjee S, Waddell T, Winton T, Shepherd FA, Tsao MS (2004) Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. Lung Cancer 46(2):197–204. doi: S0169500204001552[pii]10.1016/j.lungcan.2004.04.002

    Article  PubMed  Google Scholar 

  117. Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, Kuwano H, Takahashi T, Mitsudomi T (2004) Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 22(5):811–819. doi: 10.1200/JCO.2004.04.109JCO.2004.04.109[pii]

    Article  PubMed  CAS  Google Scholar 

  118. Liu J, Blackhall F, Seiden-Long I, Jurisica I, Navab R, Liu N, Radulovich N, Wigle D, Sultan M, Hu J, Tsao MS, Johnston MR (2004) Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. Oncogene 23(37):6316–6324. doi: 10.1038/sj.onc.12077951207795[pii]

    Article  PubMed  CAS  Google Scholar 

  119. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E (2004) A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 10(9):2922–2927

    Article  PubMed  CAS  Google Scholar 

  120. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, Yatabe Y, Takahashi T (2009) Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27(17):2793–2799. doi: JCO.2008.19.7053[pii]10.1200/JCO.2008.19.7053

    Article  PubMed  CAS  Google Scholar 

  121. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, Yang PC (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356(1):11–20. doi: 356/1/11[pii]10.1056/NEJMoa060096

    Article  PubMed  CAS  Google Scholar 

  122. Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y (2006) Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 12(11 Pt 1):3344–3354. doi: 12/11/3344[pii]10.1158/1078-0432.CCR-05-2336

    Article  PubMed  CAS  Google Scholar 

  123. Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, Sun Z, Szoke J, Gerald WL, Watson M, Govindan R, You M (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3(12):e467. doi: 06-PLME-RA-0381R2[pii]10.1371/journal.pmed.0030467

    Article  PubMed  CAS  Google Scholar 

  124. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y, Beer DG (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66(15):7466–7472. doi: 66/15/7466[pii]10.1158/0008-5472.CAN-06-1191

    Article  PubMed  CAS  Google Scholar 

  125. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP (2007) Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 117(11):3436–3444. doi: 10.1172/JCI32007

    Article  PubMed  CAS  Google Scholar 

  126. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM (2007) Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 13(10):2946–2954. doi: 13/10/2946[pii]10.1158/1078-0432.CCR-06-2525

    Article  PubMed  CAS  Google Scholar 

  127. Larsen JE, Pavey SJ, Passmore LH, Bowman R, Clarke BE, Hayward NK, Fong KM (2007) Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 28(3):760–766. doi: bgl207[pii]10.1093/carcin/bgl207

    Article  PubMed  CAS  Google Scholar 

  128. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, Johnston MR, Darling G, Keshavjee S, Waddell TK, Liu N, Lau D, Penn LZ, Shepherd FA, Jurisica I, Der SD, Tsao MS (2007) Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25(35):5562–5569. doi: 25/35/5562[pii]10.1200/JCO.2007.12.0352

    Article  PubMed  Google Scholar 

  129. Sun Z, Wigle DA, Yang P (2008) Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 26(6):877–883. doi: 26/6/877[pii]10.1200/JCO.2007.13.1516

    Article  PubMed  Google Scholar 

  130. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM (2008) A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 14(17):5565–5570. doi: 14/17/5565[pii]10.1158/1078-0432.CCR-08-0544

    Article  PubMed  CAS  Google Scholar 

  131. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J, Rosell R (2008) Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 14(15):4794–4799. doi: 14/15/4794[pii]10.1158/1078-0432.CCR-08-0576

    Article  PubMed  CAS  Google Scholar 

  132. Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC, Yang PC (2009) A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clin Cancer Res 15(23):7309–7315. doi: 1078-0432.CCR-09-1572[pii]10.1158/1078-0432.CCR-09-1572

    Article  PubMed  CAS  Google Scholar 

  133. Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II (2011) Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res 17(17):5705–5714. doi: 1078-0432.CCR-11-0196[pii]10.1158/1078-0432.CCR-11-0196

    Article  PubMed  CAS  Google Scholar 

  134. Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD (2011) Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 103(24):1859–1870. doi: djr420[pii]10.1093/jnci/djr420

    Article  PubMed  CAS  Google Scholar 

  135. Chen G, Kim S, Taylor JM, Wang Z, Lee O, Ramnath N, Reddy RM, Lin J, Chang AC, Orringer MB, Beer DG (2011) Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol 6(9):1481–1487. doi: 10.1097/JTO.0b013e31822918bd

    Article  PubMed  Google Scholar 

  136. Guo NL, Wan YW, Bose S, Denvir J, Kashon ML, Andrew ME (2011) A novel network model identified a 13-gene lung cancer prognostic signature. Int J Comput Biol Drug Des 4(1):19–39. doi: 10.1504/IJCBDD.2011.038655IJCBDD.2011.038655[pii]

    Article  PubMed  Google Scholar 

  137. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14(8):822–827. doi: nm.1790[pii]10.1038/nm.1790

    Article  PubMed  CAS  Google Scholar 

  138. Zhu CQ, Strumpf D, Li CY, Li Q, Liu N, Der S, Shepherd FA, Tsao MS, Jurisica I (2010) Prognostic gene expression signature for squamous cell carcinoma of lung. Clin Cancer Res 16(20):5038–5047. doi: 1078-0432.CCR-10-0612[pii]10.1158/1078-0432.CCR-10-0612

    Article  PubMed  CAS  Google Scholar 

  139. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS (2010) Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28(29):4417–4424. doi: JCO.2009.26.4325[pii]10.1200/JCO.2009.26.4325

    Article  PubMed  CAS  Google Scholar 

  140. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd FA, Jurisica I, Tsao MS (2011) Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 108(17):7160–7165. doi: 1014506108[pii]10.1073/pnas.1014506108

    Article  PubMed  CAS  Google Scholar 

  141. Wan YW, Beer DG, Guo NL (2011) Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma. Lung Cancer. doi: S0169-5002(11)00519-8[pii]10.1016/j.lungcan.2011.09.016

    Google Scholar 

  142. Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102(7):464–474. doi: djq025[pii]10.1093/jnci/djq025

    Article  PubMed  CAS  Google Scholar 

  143. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, Zhang L, Amur S, Bao W, Barbacioru CC, Lucas AB, Bertholet V, Boysen C, Bromley B, Brown D, Brunner A, Canales R, Cao XM, Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, Corson J, Corton JC, Croner LJ, Davies C, Davison TS, Delenstarr G, Deng X, Dorris D, Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, Hager J, Haje PK, Han J, Han T, Harbottle HC, Harris SC, Hatchwell E, Hauser CA, Hester S, Hong H, Hurban P, Jackson SA, Ji H, Knight CR, Kuo WP, LeClerc JE, Levy S, Li QZ, Liu C, Liu Y, Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, McDaniel T, Mei N, Myklebost O, Ning B, Novoradovskaya N, Orr MS, Osborn TW, Papallo A, Patterson TA, Perkins RG, Peters EH, Peterson R, Philips KL, Pine PS, Pusztai L, Qian F, Ren H, Rosen M, Rosenzweig BA, Samaha RR, Schena M, Schroth GP, Shchegrova S, Smith DD, Staedtler F, Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, Thompson KL, Tikhonova I, Turpaz Y, Vallanat B, Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, Zhong S, Zong Y, Slikker W Jr (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24(9):1151–1161. doi: nbt1239[pii]10.1038/nbt1239

    Article  PubMed  CAS  Google Scholar 

  144. Shi L, Tong W, Fang H, Scherf U, Han J, Puri RK, Frueh FW, Goodsaid FM, Guo L, Su Z, Han T, Fuscoe JC, Xu ZA, Patterson TA, Hong H, Xie Q, Perkins RG, Chen JJ, Casciano DA (2005) Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinforma 6(Suppl 2):S12. doi: 1471-2105-6-S2-S12[pii]10.1186/1471-2105-6-S2-S12

    Article  CAS  Google Scholar 

  145. Arikawa E, Sun Y, Wang J, Zhou Q, Ning B, Dial SL, Guo L, Yang J (2008) Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics 9:328. doi: 1471-2164-9-328[pii]10.1186/1471-2164-9-328

    Article  PubMed  CAS  Google Scholar 

  146. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, Hunkapiller K, Jensen RV, Knight CR, Lee KY, Ma Y, Maqsodi B, Papallo A, Peters EH, Poulter K, Ruppel PL, Samaha RR, Shi L, Yang W, Zhang L, Goodsaid FM (2006) Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 24(9):1115–1122. doi: nbt1236[pii]10.1038/nbt1236

    Article  PubMed  CAS  Google Scholar 

  147. Tyagi S, Bratu DP, Kramer FR (1998) Multicolor molecular beacons for allele discrimination. Nat Biotechnol 16(1):49–53. doi: 10.1038/nbt0198-49

    Article  PubMed  CAS  Google Scholar 

  148. Martin JA, Wang Z (2011) Next-generation transcriptome assembly. Nat Rev Genet 12(10):671–682. doi: 10.1038/nrg3068nrg3068[pii]

    Article  PubMed  CAS  Google Scholar 

  149. Kulkarni MM (2011) Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol Chapter 25, Unit25B 10. doi: 10.1002/0471142727.mb25b10s94

    Google Scholar 

  150. Affymetrix (2002) Statistical algorithms description document. Affymetrix, Inc., Santa Clara

    Google Scholar 

  151. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31(4):e15

    Article  PubMed  CAS  Google Scholar 

  152. Wu Z, Irizarry RA (2004) Preprocessing of oligonucleotide array data. Nat Biotechnol 22(6):656–658. doi: 10.1038/nbt0604-656bnbt0604-656b[pii]

    Article  PubMed  CAS  Google Scholar 

  153. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98(1):31–36. doi: 10.1073/pnas.011404098011404098[pii]

    Article  PubMed  CAS  Google Scholar 

  154. Millenaar FF, Okyere J, May ST, van Zanten M, Voesenek LA, Peeters AJ (2006) How to decide? Different methods of calculating gene expression from short oligonucleotide array data will give different results. BMC Bioinforma 7:137. doi: 1471-2105-7-137[pii]10.1186/1471-2105-7-137

    Article  CAS  Google Scholar 

  155. Cope LM, Irizarry RA, Jaffee HA, Wu Z, Speed TP (2004) A benchmark for Affymetrix GeneChip expression measures. Bioinformatics 20(3):323–331. doi: 10.1093/bioinformatics/btg41020/3/323[pii]

    Article  PubMed  CAS  Google Scholar 

  156. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249–264. doi: 10.1093/biostatistics/4.2.2494/2/249[pii]

    Article  PubMed  Google Scholar 

  157. Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti GV, Douillard JY, Spiro S, Shepherd FA (2008) Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26(21):3573–3581. doi: 26/21/3573[pii]10.1200/JCO.2008.16.2727

    Article  PubMed  CAS  Google Scholar 

  158. Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA (2007) Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25(12):1553–1561. doi: 25/12/1553[pii]10.1200/JCO.2006.09.5570

    Article  PubMed  CAS  Google Scholar 

  159. Hartwell LH, Hopfield JJ, Leibler S, Murray AW (1999) From molecular to modular cell biology. Nature 402(6761 Suppl):C47–C52. doi: 10.1038/35011540

    Article  PubMed  CAS  Google Scholar 

  160. Chuang HY, Lee E, Liu YT, Lee D, Ideker T (2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3:140. doi: msb4100180[pii]10.1038/msb4100180

    Article  PubMed  Google Scholar 

  161. Csermely P, Agoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26(4):178–182. doi: S0165-6147(05)00055-6[pii]10.1016/j.tips.2005.02.007

    Article  PubMed  CAS  Google Scholar 

  162. Sotiriou C, Piccart MJ (2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7(7):545–553. doi: nrc2173[pii]10.1038/nrc2173

    Article  PubMed  CAS  Google Scholar 

  163. Hai J, Zhu CQ, Bandarchi B, Wang YH, Navab R, Shepherd FA, Jurisica I, Tsao MS (2012) L1 cell adhesion molecule (L1CAM) promotes tumorigenicity and metastatic potential in non-small-cell lung cancer. Clin Cancer Res 18:1914–1924

    Article  PubMed  CAS  Google Scholar 

  164. Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development 132(21):4653–4662. doi: 10.1242/dev.02073

    Article  PubMed  CAS  Google Scholar 

  165. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297

    Article  PubMed  CAS  Google Scholar 

  166. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524–15529. doi: 10.1073/pnas.242606799

    Article  PubMed  CAS  Google Scholar 

  167. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834–838. doi: 10.1038/nature03702

    Article  PubMed  CAS  Google Scholar 

  168. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res MCR 1(12):882–891

    CAS  Google Scholar 

  169. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11):3753–3756. doi: 10.1158/0008-5472.CAN-04-0637

    Article  PubMed  CAS  Google Scholar 

  170. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7(6):759–764

    Article  PubMed  CAS  Google Scholar 

  171. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105(10):3903–3908. doi: 10.1073/pnas.0712321105

    Article  PubMed  CAS  Google Scholar 

  172. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065–7070. doi: 10.1158/0008-5472.CAN-05-1783

    Article  PubMed  CAS  Google Scholar 

  173. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S, Croce CM (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67(18):8699–8707. doi: 10.1158/0008-5472.CAN-07-1936

    Article  PubMed  CAS  Google Scholar 

  174. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD (2007) Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120(5):1046–1054. doi: 10.1002/ijc.22394

    Article  PubMed  CAS  Google Scholar 

  175. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3):189–198. doi: 10.1016/j.ccr.2006.01.025

    Article  PubMed  CAS  Google Scholar 

  176. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257–2261. doi: 10.1073/pnas.0510565103

    Article  PubMed  CAS  Google Scholar 

  177. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG (2009) MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69(14):5776–5783. doi: 10.1158/0008-5472.CAN-09-0587

    Article  PubMed  CAS  Google Scholar 

  178. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J (2011) A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 17(21):6802–6811. doi: 10.1158/1078-0432.CCR-11-0419

    Article  PubMed  CAS  Google Scholar 

  179. Yang Y, Li X, Yang Q, Wang X, Zhou Y, Jiang T, Ma Q, Wang YJ (2010) The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogenet 200(2):127–133. doi: 10.1016/j.cancergencyto.2010.03.014

    Article  PubMed  CAS  Google Scholar 

  180. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27(12):2030–2037. doi: 10.1200/JCO.2008.19.4134

    Article  PubMed  CAS  Google Scholar 

  181. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH (2010) Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16(2):610–619. doi: 10.1158/1078-0432.CCR-09-2638

    Article  PubMed  CAS  Google Scholar 

  182. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N (2009) miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 69(6):2287–2295. doi: 10.1158/0008-5472.CAN-08-2894

    Article  PubMed  CAS  Google Scholar 

  183. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593–601. doi: 10.1038/ncb1722

    Article  PubMed  CAS  Google Scholar 

  184. Wu H, Zhu S, Mo YY (2009) Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19(4):439–448. doi: 10.1038/cr.2009.18

    Article  PubMed  CAS  Google Scholar 

  185. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, Yamamura S, Ueno K, Zaman MS, Singh K, Chang I, Deng G, Dahiya R (2011) MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res 71(7):2611–2621. doi: 10.1158/0008-5472.CAN-10-3666

    Article  PubMed  CAS  Google Scholar 

  186. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, McShane LM, Wang E (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16(2):430–441. doi: 10.1158/1078-0432.CCR-09-1736

    Article  PubMed  CAS  Google Scholar 

  187. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1):48–57. doi: 10.1016/j.ccr.2007.12.008

    Article  PubMed  CAS  Google Scholar 

  188. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S (2010) Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 70(1):36–45. doi: 10.1158/0008-5472.CAN-09-3153

    Article  PubMed  CAS  Google Scholar 

  189. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635–647. doi: 10.1016/j.cell.2005.01.014

    Article  PubMed  CAS  Google Scholar 

  190. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y (2010) Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 64(6):399–408. doi: 10.1016/j.biopha.2010.01.018

    Article  PubMed  CAS  Google Scholar 

  191. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathe EA, Takenoshita S, Yokota J, Haugen A, Harris CC (2011) The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 17(7):1875–1882. doi: 10.1158/1078-0432.CCR-10-2961

    Article  PubMed  CAS  Google Scholar 

  192. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES (2008) Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54(10):1696–1704. doi: 10.1373/clinchem.2007.101741

    Article  PubMed  CAS  Google Scholar 

  193. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH (2010) MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411(11–12):846–852. doi: 10.1016/j.cca.2010.02.074

    Article  PubMed  CAS  Google Scholar 

  194. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN (2010) Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18(3):282–293. doi: 10.1016/j.ccr.2010.08.013

    Article  PubMed  CAS  Google Scholar 

  195. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31):4373–4379. doi: 10.1038/onc.2008.72

    Article  PubMed  CAS  Google Scholar 

  196. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283(2):1026–1033. doi: 10.1074/jbc.M707224200

    Article  PubMed  CAS  Google Scholar 

  197. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19):14328–14336. doi: 10.1074/jbc.M611393200

    Article  PubMed  CAS  Google Scholar 

  198. Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A, Bello AM, De Luca P, Calabrese C, Fusco A, Ceccarelli M, Zollo M, Barbacid M, Di Lauro R, De Vita G (2011) Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30(3):275–286. doi: 10.1038/onc.2010.416

    Article  PubMed  CAS  Google Scholar 

  199. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, Khan MA, Hainaut P, Pignon JP, Brambilla E, Popper HH, Filipits M, Harris CC, Giaccone G (2010) MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70(21):8288–8298. doi: 10.1158/0008-5472.CAN-10-1348

    Article  PubMed  CAS  Google Scholar 

  200. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J (2010) Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol 5(11):1755–1763. doi: 10.1097/JTO.0b013e3181f3909d

    Article  PubMed  Google Scholar 

  201. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA (2008) EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19(6):1053–1059. doi: 10.1093/annonc/mdn006

    Article  PubMed  CAS  Google Scholar 

  202. Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, Landsvater RM, de Leij LF, Berendsen HH, Postmus PE et al (1987) Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330(6148):578–581. doi: 10.1038/330578a0

    Article  PubMed  CAS  Google Scholar 

  203. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW 3rd, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD (2000) High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60(7):1949–1960

    PubMed  CAS  Google Scholar 

  204. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518. doi: 10.1073/pnas.0804549105

    Article  PubMed  CAS  Google Scholar 

  205. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13(10):1668–1674. doi: 10.1261/rna.642907

    Article  PubMed  CAS  Google Scholar 

  206. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006. doi: 10.1038/cr.2008.282

    Article  PubMed  CAS  Google Scholar 

  207. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F (2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Inv 91(4):579–587. doi: 10.1038/labinvest.2010.194

    Article  CAS  Google Scholar 

  208. Xing L, Todd NW, Yu L, Fang H, Jiang F (2010) Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 23(8):1157–1164. doi: 10.1038/modpathol.2010.111

    Article  PubMed  CAS  Google Scholar 

  209. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX (2011) Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 4(6):575–586

    PubMed  CAS  Google Scholar 

  210. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S, Zhuang R, Zhang Y, Hu H, Liu C, Xu L, Wang J, Shen H, Zhang J, Zen K, Zhang CY (2011) Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. doi: 10.1002/ijc.26177

    Google Scholar 

  211. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC (2011) Circulating microRNA expression profiles in early stage non-small cell lung cancer. Int J Cancer. doi: 10.1002/ijc.26153

    Google Scholar 

  212. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28(10):1721–1726. doi: 10.1200/JCO.2009.24.9342

    Article  PubMed  Google Scholar 

  213. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F (2010) Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67(2):170–176. doi: 10.1016/j.lungcan.2009.04.004

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported in part by the Ontario Research Fund Research Excellence Award (RE-03–020) from the Ontario Ministry of Research and Innovation, and the Ontario Ministry of Health and Long Term Care. Shirley Tam is supported by the Ontario Graduate Studentship. Dr. Tsao is the M Qasim Choksi Chair in Lung Cancer Translational Research.

Author information

Authors and Affiliations

  1. Pathology, University Health Network, Toronto, ON, Canada

    Kenneth J. Craddock & Chang-Qi Zhu

  2. Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

    Shirley Tam & Ming-Sound Tsao

  3. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

    Shirley Tam & Ming-Sound Tsao

  4. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

    Ming-Sound Tsao

Authors
  1. Kenneth J. Craddock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shirley Tam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang-Qi Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming-Sound Tsao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth J. Craddock .

Editor information

Editors and Affiliations

  1. , Integrated Molecular Pathology, National Cancer Research Institute, Largo Rosanna Benzi 10, Genova, 16132, Italy

    Ulrich Pfeffer

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Craddock, K.J., Tam, S., Zhu, CQ., Tsao, MS. (2013). Genomic Pathology of Lung Cancer. In: Pfeffer, U. (eds) Cancer Genomics. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5842-1_1

Download citation

Publish with us

Policies and ethics

Search

Navigation